Đang chuẩn bị liên kết để tải về tài liệu:
Oral proteasome inhibitor with strong preclinical efficacy in myeloma models

The proteasome is a validated anti-cancer target and various small-molecule inhibitors are currently in clinical development or on the market. However, adverse events and resistance associated with those proteasome inhibitors indicate the need for a new generation of drugs. |